Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids.
Effective medications for drug abuse remain a largely unmet goal in biomedical science. Recently, the (+)-enantiomers of naloxone and naltrexone, TLR4 antagonists, have been reported to attenuate preclinical indicators of both opioid and stimulant abuse. To further examine the potential of these compounds as drug-abuse treatments, we extended the previous assessments to include a wider range of doses and procedures. We report the assessment of (+)-naloxone and (+)-naltrexone on the acute dopaminergic effects of cocaine and heroin determined by in vivo microdialysis, on the reinforcing effects of cocaine and the opioid agonist, remifentanil, tested under intravenous self-administration procedures, as well as the subjective effects of cocaine determined by discriminative-stimulus effects in rats. Pretreatments with (+)-naloxone or (+)-naltrexone did not attenuate, and under certain conditions enhanced the stimulation of dopamine levels produced by cocaine or heroin in the nucleus accumbens shell. Furthermore, although an attenuation of either cocaine or remifentanil self-administration was obtained at the highest doses of (+)-naloxone and (+)-naltrexone, those doses also attenuated rates of food-maintained behaviors, indicating a lack of selectivity of TLR4 antagonist effects for behaviors reinforced with drug injections. Drug-discrimination studies failed to demonstrate a significant interaction of (+)-naloxone with subjective effects of cocaine. The present studies demonstrate that under a wide range of doses and experimental conditions, the TLR4 antagonists, (+)-naloxone and (+)-naltrexone, did not specifically block neurochemical or behavioral abuse-related effects of cocaine or opioid agonists.
Medication Development Program, Molecular Targets and Medication Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
Gianluigi
0000-0001-9526-9878
G
Tanda
Medication Development Program, Molecular Targets and Medication Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
Maddalena
M
Mereu
Psychobiology Section, Molecular Neuropsychiatry Research Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
Takato
T
Hiranita
Medication Development Program, Molecular Targets and Medication Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
Juliana C
JC
Quarterman
Medication Development Program, Molecular Targets and Medication Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
Mark
M
Coggiano
Psychobiology Section, Molecular Neuropsychiatry Research Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
Jonathan L
JL
Katz
D000701:Analgesics, Opioid / Q000494:pharmacology; D000777:Anesthetics / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003042:Cocaine / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects*; D004192:Discrimination, Psychological / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D005108:Extinction, Psychological / Q000187:drug effects; D008297:Male; D017551:Microdialysis; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012054:Reinforcement, Psychology; D000077208:Remifentanil; D012646:Self Administration; D013997:Time Factors
D000701:Analgesics, Opioid; D000777:Anesthetics; D009292:Narcotic Antagonists; D010880:Piperidines; D009270:Naloxone; D009271:Naltrexone; D003042:Cocaine; D000077208:Remifentanil; D004298:Dopamine